Trial Profile

A Phase Ib, Dose Finding Study Evaluating AZD1775 in Monotherapy, in Combination With Carboplatin and Paclitaxel, and in Combination With Only Carboplatin in Adult Asian Patients With Advanced Solid Tumours

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Adavosertib (Primary) ; Carboplatin; Paclitaxel
Indications Advanced breast cancer; Cervical intraepithelial neoplasia; Head and neck cancer; Ovarian cancer; Solid tumours; Uterine cancer
Focus Adverse reactions
Sponsors AstraZeneca

07 Feb 2020 Safety results published in the Targeted Oncology.
09 Nov 2017 Status changed from active, no longer recruiting to completed.
30 Oct 2017 Results assessing safety presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com